Skip to main content
  • Advertise
    Want to Advertise with Us?
    Conquer welcomes advertising and sponsorship collaborations with reputable companies offering high-quality products and services to people affected by cancer.
  • Affiliated Brands
    Academy of Oncology Nurse & Patient Navigators
    The Academy of Oncology Nurse & Patient Navigators (AONN+) is the largest national specialty organization dedicated to improving patient care and quality of life by defining, enhancing, and promoting the role of oncology nurse and patient navigators. Our organization of over 8,900 members was founded in May 2009 to provide a network for all professionals involved and interested in patient navigation and survivorship care services to better manage the complexities of the cancer care treatment continuum for their patients. We view our organization as one consisting of “professional patient advocates” and, to that end, we support and serve our members.
    Journal of Oncology Navigation & Survivorship
    The Journal of Oncology Navigation & Survivorship (JONS) promotes reliance on evidence-based practices in navigating patients with cancer and their caregivers through diagnosis, treatment, and survivorship. JONS also seeks to strengthen the role of nurse and patient navigators in cancer care by serving as a platform for these professionals to disseminate original research findings, exchange best practices, and find support for their growing community.
    The Oncology Nurse-APN/PA
    The Oncology Nurse-APN/PA (TON) provides coverage of the wide spectrum of oncology-related events, trends, news, therapeutics, diagnostics, organizations, and legislation that directly affect hematology/oncology nurses and advanced practitioners involved in healthcare delivery and product utilization. The scope and coverage include a unique presentation of news and events that are shaping the care of patients with cancer.
  • Healthcare Providers
  • Contribute

Web Exclusives

Oncology Social Workers: The Unsung Heroes of the Cancer Journey
Web Exclusives — March 15, 2022
Doctors and nurses are heroes for the care they provide, and researchers are heroes for the breakthrough treatments and medications they develop. Let us not overlook the incredible contributions of oncology social workers in the journey of a patient with cancer. Read More ›

A Healthy Diet May Reduce the Risk of Cancer
Web Exclusives — February 8, 2022
Based on current and evolving scientific evidence, the cancer prevention guidelines have been shifting from a nutrient-centric approach to a more holistic approach of diet that is characterized as dietary patterns. Read More ›

Close the Gap in Cancer Care: We Are All Interconnected in Wellness

Can You Get Pregnant If You Have Cervical Cancer?
Web Exclusives — January 13, 2022
Cervical cancer during pregnancy can be successfully managed with a multidisciplinary treatment team and an individualized treatment strategy that optimizes maternal treatment while considering fetal safety. Read More ›

FDA Approved Fyarro for Malignant Perivascular Epithelioid-Cell Tumor
Web Exclusives — December 21, 2021

On November 22, 2021, the FDA approved Fyarro (sirolimus protein-bound particles for injectable suspension (albumin-bound); from Aadi Bioscience) for adults with locally advanced, unresectable or metastatic malignant perivascular epithelioid-cell tumor (PEComa), a rare type of mesenchymal tumors that can occur in any part of the body.

Read More ›

Jemperli a New Immunotherapy Approved for All Patients with dMMR Solid Tumors
Web Exclusives — December 14, 2021
On August 17, 2021, the FDA accelerated the approval of Jemperli (dostarlimab-gxly; from GlaxoSmithKline) injection, an immunotherapy and a PD-1 inhibitor, for the treatment of all adults with recurrent (coming back) or advanced mismatch repair-deficient (dMMR) solid tumors, including lung cancer, that progressed during or after systemic therapy and for whom there are no satisfactory alternative treatment options. Read More ›

Reasons for Optimism for Patients with Cancer Facing Another Winter with COVID-19
Web Exclusives — December 1, 2021
Although we are entering another winter with the ongoing prevalence of the coronavirus, we have come a long way since the initial outbreak. Here are some reasons for patients to be optimistic for the season. Read More ›

Combining Targeted Therapies in CLL
Web Exclusives — November 17, 2021
The combination of acalabrutinib, venetoclax, and obinutuzumab has been shown to be an active regimen in previously untreated patients with CLL. Read More ›

A Comprehensive Analysis of COVID-19 in Patients with CLL
Web Exclusives — November 17, 2021
During the first 13 months of the pandemic, COVID-19 continued to result in high hospitalization rates among patients with CLL. Read More ›

Infections in Patients with CLL Receiving Ibrutinib
Web Exclusives — November 17, 2021
Identifying the risk factors for infection may allow preventive measures to be taken to protect patients. Read More ›

Page 3 of 25